terfenadine has been researched along with Electrocardiogram QT Prolonged in 48 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of drug-induced long QT syndrome." | 7.85 | Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "A 36-year-old female was given terfenadine 120 mg/day for hay fever, and itraconazole 100 mg twice daily for mycosis." | 7.69 | [Syncopes during simultaneous use of terfenadine and itraconazole]. ( Froger, CL; Romkes, JH; Westerhof, PW; Wever, EF, 1997) |
| "Terfenadine is a widely used antihistamine." | 5.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| "Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades." | 3.85 | Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism. ( Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M, 2017) |
| "Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of drug-induced long QT syndrome." | 3.85 | Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T, 2017) |
| "For terfenadine, TRIaD predicts drug-induced proarrhythmia: with λ prolongation, Torsade de Pointes is preferred, otherwise ventricular tachycardia/ventricular fibrillation." | 3.77 | Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. ( De Clerck, F; Dujardin, K; Dumotier, B; Hoffmann, P; Hondeghem, LM, 2011) |
| "Administration of the antihistamine terfenadine (Seldane) to patients may result in acquired long QT syndrome and ventricular arrhythmias." | 3.69 | HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. ( Brown, AM; Dumaine, R; Roy, M, 1996) |
| "A 36-year-old female was given terfenadine 120 mg/day for hay fever, and itraconazole 100 mg twice daily for mycosis." | 3.69 | [Syncopes during simultaneous use of terfenadine and itraconazole]. ( Froger, CL; Romkes, JH; Westerhof, PW; Wever, EF, 1997) |
| "Terfenadine has been reported to cause cardiac death." | 1.38 | Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? ( Gallacher, DJ; Hermans, AN; Lu, HR, 2012) |
| "The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
| "Terfenadine is a widely used antihistamine." | 1.29 | Torsade de pointes induced by terfenadine in a patient with long QT syndrome. ( Kim, SS; Koh, KK; Rim, MS; Yoon, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (29.17) | 18.2507 |
| 2000's | 25 (52.08) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 1 |
| Zhang, HC | 1 |
| Derian, CK | 1 |
| McComsey, DF | 1 |
| White, KB | 1 |
| Ye, H | 1 |
| Hecker, LR | 1 |
| Li, J | 1 |
| Addo, MF | 1 |
| Croll, D | 1 |
| Eckardt, AJ | 1 |
| Smith, CE | 1 |
| Li, Q | 1 |
| Cheung, WM | 1 |
| Conway, BR | 1 |
| Emanuel, S | 1 |
| Demarest, KT | 1 |
| Andrade-Gordon, P | 1 |
| Damiano, BP | 1 |
| Maryanoff, BE | 1 |
| Bonate, PL | 1 |
| Yan, M | 1 |
| Feng, L | 1 |
| Shi, Y | 1 |
| Wang, J | 1 |
| Liu, Y | 1 |
| Li, F | 1 |
| Li, B | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Nakamura, Y | 3 |
| Matsukura, S | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Naito, AT | 1 |
| Sugiyama, A | 6 |
| Romero, L | 1 |
| Trenor, B | 1 |
| Yang, PC | 1 |
| Saiz, J | 1 |
| Clancy, CE | 1 |
| Wiśniowska, B | 1 |
| Polak, S | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Grilo, LS | 1 |
| Carrupt, PA | 1 |
| Daina, A | 1 |
| Hondeghem, LM | 1 |
| Dujardin, K | 1 |
| Hoffmann, P | 1 |
| Dumotier, B | 1 |
| De Clerck, F | 1 |
| Lu, HR | 1 |
| Hermans, AN | 1 |
| Gallacher, DJ | 1 |
| Pareja, K | 1 |
| Chu, E | 1 |
| Dodyk, K | 1 |
| Richter, K | 1 |
| Miller, A | 1 |
| Fossa, AA | 1 |
| DePasquale, MJ | 1 |
| Raunig, DL | 1 |
| Avery, MJ | 1 |
| Leishman, DJ | 1 |
| Satoh, Y | 3 |
| Takahara, A | 4 |
| Shimizu-Sasamata, M | 1 |
| Sato, S | 1 |
| Miyata, K | 1 |
| Hashimoto, K | 5 |
| Brown, AM | 2 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Heist, EK | 1 |
| Ruskin, JN | 1 |
| Ishida, Y | 1 |
| Wang, K | 1 |
| Roden, DM | 1 |
| Rufke, C | 1 |
| Nieber, K | 1 |
| Moss, AJ | 1 |
| Crumb, W | 1 |
| Llorca, PM | 1 |
| Lancon, C | 1 |
| Thomas, GP | 1 |
| Garay, RP | 1 |
| Hameg, A | 1 |
| Sisáková, M | 1 |
| Toman, O | 1 |
| Floriánová, A | 1 |
| Kadlecová, J | 1 |
| Chroust, K | 1 |
| Papousek, I | 1 |
| Spinar, J | 1 |
| Couderc, JP | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Moneret-Vautrin, DA | 1 |
| de Chillou, C | 1 |
| Codreanu, A | 1 |
| Hughes, DA | 1 |
| Bayoumi, AM | 1 |
| Pirmohamed, M | 1 |
| Koh, KK | 1 |
| Rim, MS | 1 |
| Yoon, J | 1 |
| Kim, SS | 1 |
| Barragán Acea, A | 1 |
| García González, M | 1 |
| Rodríguez Gaspar, M | 1 |
| de Armas Trujillo, D | 1 |
| Conti, CR | 1 |
| Flockhart, DA | 1 |
| Rosen, MR | 1 |
| Roy, M | 1 |
| Dumaine, R | 1 |
| Romkes, JH | 1 |
| Froger, CL | 1 |
| Wever, EF | 1 |
| Westerhof, PW | 1 |
| Pasco, J | 1 |
| Pinto, YM | 1 |
| van Gelder, IC | 1 |
| Heeringa, M | 1 |
| Crijns, HJ | 1 |
| Weber, KT | 1 |
| Shuster, J | 1 |
| Khilnani, G | 1 |
| Dhar, S | 1 |
| Hazra, PK | 1 |
| Malakar, S | 1 |
| Mistri, G | 1 |
| Rajamani, S | 1 |
| Anderson, CL | 1 |
| Anson, BD | 1 |
| January, CT | 1 |
| Feychting, K | 1 |
| Myrenfors, P | 1 |
| Zimmermann, M | 1 |
| Duruz, H | 1 |
| Guinand, O | 1 |
| Broccard, O | 1 |
| Levy, P | 1 |
| Lacatis, D | 1 |
| Bloch, A | 1 |
7 reviews available for terfenadine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cat | 2003 |
Drugs, hERG and sudden death.
Topics: Death, Sudden, Cardiac; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassiu | 2004 |
Long QT syndrome: reduced repolarization reserve and the genetic link.
Topics: Anti-Arrhythmia Agents; Disease Susceptibility; Female; Genotype; Histamine H1 Antagonists; Humans; | 2006 |
[Long QT interval. Interaction of terfenadine and itraconazole].
Topics: Antifungal Agents; Histamine H1 Antagonists; Humans; Itraconazole; Long QT Syndrome; Onychomycosis; | 2006 |
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Of oocytes and runny noses.
Topics: Animals; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Pota | 1996 |
41 other studies available for terfenadine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
Topics: Animals; Cell Line; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glycogen Synthase Kina | 2005 |
QTc interval analysis-an ever-evolving endeavor.
Topics: Dose-Response Relationship, Drug; Drug Approval; Drug Recalls; Electrocardiography; Humans; Long QT | 2021 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK2 | 2017 |
Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome.
Topics: Anesthetics, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Disease Models, Animal; Dose | 2017 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expressi | 2014 |
Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example.
Topics: Adult; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Histamine H1 | 2016 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Stereoselective block of hERG channel by bupivacaine scrutinized at molecular level.
Topics: Bupivacaine; Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Models | 2010 |
Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine.
Topics: Action Potentials; Animals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart; Hi | 2011 |
Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Biological Transport; Cells, C | 2012 |
Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.
Topics: Bepridil; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Potass | 2013 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart | 2002 |
Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Topics: Action Potentials; Animals; Cation Transport Proteins; Cell Line; DNA-Binding Proteins; Dogs; Electr | 2003 |
Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
Topics: Action Potentials; Adrenergic beta-Antagonists; Algorithms; Anesthetics, Inhalation; Animals; Chroma | 2005 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.
Topics: Anti-Arrhythmia Agents; Antipsychotic Agents; Histamine H1 Antagonists; Humans; Long QT Syndrome; Ri | 2005 |
Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.
Topics: Animals; Atrioventricular Node; Bradycardia; Catheter Ablation; Dogs; Dose-Response Relationship, Dr | 2006 |
Drug-induced QT prolongation: an update.
Topics: Electrocardiography; Fluoroquinolones; Humans; Long QT Syndrome; Quinidine; Terfenadine | 2006 |
Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Calcium Channels; Cell Line; Dose-Response Relat | 2006 |
[Extension of QT interval as a consequence of risk factor accumulation--case study].
Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Drug Interactions; Female; Histamin | 2006 |
QT interval prolongation and beyond.
Topics: Animals; Anti-Allergic Agents; Dogs; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Terf | 2006 |
Comparison of four rate-correction algorithms for the ventricular repolarization period in assessing net effects of IKr blockers in dogs.
Topics: Action Potentials; Algorithms; Animals; Blood Pressure; Delayed Rectifier Potassium Channels; Dogs; | 2006 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
Topics: Algorithms; Anti-Allergic Agents; Decision Support Techniques; Government Regulation; Humans; Long Q | 2007 |
Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
Topics: Adult; Electrocardiography; Female; Humans; Long QT Syndrome; Terfenadine; Torsades de Pointes; Urti | 1994 |
[Ventricular arrhythmia induced by terfenadine treatment].
Topics: Adult; Female; Humans; Long QT Syndrome; Terfenadine | 1995 |
The nonsedating antihistamine scare.
Topics: Astemizole; Drug Interactions; Drug Therapy, Combination; Humans; Long QT Syndrome; Terfenadine | 1994 |
Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?
Topics: Death, Sudden, Cardiac; Drug Interactions; Heart; Histamine H1 Antagonists; Humans; Long QT Syndrome | 1996 |
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
Topics: Animals; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Pota | 1996 |
[Syncopes during simultaneous use of terfenadine and itraconazole].
Topics: Adult; Anti-Allergic Agents; Antifungal Agents; Cardiotonic Agents; Female; Humans; Isoproterenol; I | 1997 |
What has the patient been taking?
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chlorothiazide; Cimetidine; Diagnosis, Differential; | 1998 |
QT lengthening and life-threatening arrhythmias associated with fexofenadine.
Topics: Aged; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Syncope; Tachyc | 1999 |
A dilemma on Orchid Island.
Topics: Aged; Beverages; Citrus; Glycyrrhiza; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Plan | 1999 |
Fexofenadine and prolonged QT intervals.
Topics: Aged; Drug Monitoring; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male | 1999 |
Terfenadine should be withdrawn from clinical use.
Topics: Drug Interactions; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenad | 1999 |
Fexofenadine-induced QT prolongation: a myth or fact?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenadine | 2000 |
Severe cardiac arrhythmia on fexofenadine?
Topics: Adverse Drug Reaction Reporting Systems; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfena | 2000 |
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Electric Conductivity; ERG1 Pot | 2002 |
[Severe effects of terfenadine overdose on the heart].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Heart Rate; Human | 1992 |
Torsades de Pointes after treatment with terfenadine and ketoconazole.
Topics: Adult; Cardiac Pacing, Artificial; Dermatomycoses; Drug Therapy, Combination; Electrocardiography, A | 1992 |